Decision: Favourable

Decisions Table

Study Title:

A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR- 707) combined with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers

  • NREC Code:

    21-NREC-CT-069

  • Decision:

    Favourable

  • Meeting Date:

    11/08/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Prof John Crown

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Sanofi-aventis Recherche & Développement

Scroll to Top